Filing Flows › Harmony Biosciences Holdings (HRMY) › Q3 2026 › vs Q2 2026
Harmony Biosciences Holdings (HRMY) Q3 2026 vs Q2 2026 (quarter over quarter)
Harmony Biosciences Holdings's revenue rose $7.6M (+3%) from $261M in Q2 2026 to $269M in Q3 2026. Gross margin 70.0% against 75.8% (-5.8 pts).
Harmony Biosciences Holdings, Q3 2026: revenue $269M (+12% year over year), operating margin 20.2%, net earnings $48.2M, operating cash flow $76.7M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 70.0% | 75.8% | -5.8 pts |
| Operating margin | 20.2% | 34.2% | -14.0 pts |
| Net margin | 17.9% | 28.9% | -10.9 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $269M | $261M | $7.6M | +3% |
| Gross profit | $188M | $198M | −$9.9M | -5% |
| Cost of revenue | $80.7M | $63.2M | $17.5M | +28% |
| Other income, net | $5.1M | $3.9M | $1.1M | +28% |
| Operating profit | $54.2M | $89.3M | −$35.1M | -39% |
| Operating expenses | $134M | $109M | $25.3M | +23% |
| Pre-tax earnings | $59.2M | $93.3M | −$34.0M | -36% |
| Research & development | $71.7M | $46.6M | $25.1M | +54% |
| Sales & marketing | $34.7M | $34.1M | $601K | +2% |
| General & admin | $27.6M | $28.1M | −$400K | -1% |
| Net earnings | $48.2M | $75.4M | −$27.2M | -36% |
| Income tax | $11.1M | $17.8M | −$6.8M | -38% |
| Depreciation & amortization | $6.0M | $6.0M | $0 | 0% |
| Share-based compensation | $8.0M | $9.3M | −$1.3M | -14% |
| Working capital & other | $14.5M | $1.7M | $12.8M | +753% |
| Operating cash flow | $76.7M | $92.4M | −$15.7M | -17% |
Questions
How much did Harmony Biosciences Holdings's revenue grow quarter over quarter in Q3 2026?
Harmony Biosciences Holdings's revenue rose $7.6M (+3%) from $261M in Q2 2026 to $269M in Q3 2026. Gross margin 70.0% against 75.8% (-5.8 pts).